ClinicalTrials.gg
TerminatedNCT03745222RATIONALE001Updated Jul 15, 2020Results posted

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

A Phase 3 interventional study of Tislelizumab and Concurrent chemoradiotherapy (cCRT) in Carcinoma, Non-Small-Cell Lung, sponsored by Celgene. Terminated at 164 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-15.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Why this study was terminated
BeiGene and Celgene Corporation terminated the parties' global collaboration for the compound, pending the acquisition of Celgene by Bristol Myers Squibb

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 22 under way, 2 of them phase 3. tislelizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
40th of 41
1 · median 39
Started
2019
the only one that year
Phase 3
9 of 41
none open now
Registered
4th of 41
by date
Lead sponsor
1 of 41
Celgene

Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 40th largest by enrollment, is the only one that started in 2019, is one of 9 in phase 3, and was the 4th registered.

Carcinoma, Non-Small-Cell Lung

7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, double-blind, placebo-controlled multicenter global study designed to compare the efficacy and safety of tislelizumab in combination with concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy versus cCRT alone, and tislelizumab given sequentially after cCRT versus cCRT alone, in newly diagnosed stage III subjects with locally advanced, unresectable non-small cell lung cancer (NSCLC). The primary endpoint is centrally-assessed progression free survival (PFS) in the intent-to-treat (ITT) population. .

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Locally Advanced, Unresectable Non-Small Cell Lung Cancer
  • Non-Small Cell Lung Cancer
  • NSCLC
  • Randomized
  • BGB-A317
  • Tislelizumab
  • PD-1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newly diagnosed, confirmed, locally advanced, stage III unresectable non small cell lung cancer (NSCLC).

    Staging will be confirmed at screening by positron emission tomography-computed tomography (PET/CT) and brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) with contrast.

  2. (ECOG) performance status ≤ 1.
  3. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) gene translocation status available prior to randomization.
  4. Provision of fresh or or discussion with Sponsor.
  5. Adequate hematologic and end-organ function.

Exclusion criteria

Exclusion Criteria:

  1. Prior therapies including those targeting or PD-L1 or chemotherapy, radiation, targeted therapy, biologic therapy, immunotherapy or agent used to control non-small cell lung cancer (NSCLC).
  2. History of severe reactions to other monoclonal antibodies or any to the planned chemotherapy regimen.
  3. History of, or ongoing, interstitial lung disease; pneumonitis requiring ; or pericardial effusion.
  4. Any active less than or equal to 2 years before randomization, with the exception of non-small cell lung cancer (NSCLC) and any locally recurring cancer that has been treated curatively.
  5. Severe chronic or active infections including those requiring systemic antibacterial, antifungal or antiviral therapy; known (HIV) infection; untreated chronic or chronic hepatitis B virus carries or active ; or active disease.
  6. Prior stem cell transplantation or organ transplantation.
  7. Significant cardiovascular disease or other condition which places the patient at risk.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Arm 1:Tislelizumab + cCRT followed by tislelizumab monotherapy

    Tislelizumab 200 mg is administered by intravenous (IV) administration and given together upfront with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV adminstration monotherapy. The standard platinum-based chemotherapy options include carboplatin/ paclitaxel and cisplatin/etoposide

    Drug: Tislelizumab · Drug: Concurrent chemoradiotherapy (cCRT)

  • Experimental
    Arm 2: Placebo + cCRT followed by tislelizumab monotherapy

    Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV administration monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.

    Drug: Tislelizumab · Drug: Concurrent chemoradiotherapy (cCRT) · Other: Placebo

  • Placebo comparator
    Arm 3: Placebo + cCRT followed by placebo monotherapy

    Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by placebo monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.

    Drug: Concurrent chemoradiotherapy (cCRT) · Other: Placebo

Interventions

  • PD-1 inhibitor (monoclonal antibody against PD-1)

    Also known as: BGB-A317

  • DrugConcurrent chemoradiotherapy (cCRT)

    Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Progression-free survival was defined as the time from the date of randomization to the date of the first objectively tumor progression as assessed by the blinded independent central review per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by radiological assessment) or death (any cause) on or prior to the clinical cut-off date, which ever occurred first. Stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for Progressive disease (PD)• Progressive Disease- At least a 20% increase in the sum of diameters of target lesions from nadir.

    Time frame: Up to approximately 5 years; date of randomization to the date of tumor progression or death; until study withdrawal date of 26 June 2019

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival was defined as the time between randomization of treatment and death from any cause.

    Time frame: Up to approximately 5 years; date of randomization to date of death from any cause.

  2. Overall Survival at 24 Months

    Overall survival was defined as the time between randomization of treatment and death from any cause.

    Time frame: Up to approximately 24 months

  3. Percentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response

    Overall Response was defined as percentage of participants who had a radiologic confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) guidelines, between Day 1 of treatment and subsequent anti-cancer therapy, death or study discontinuation. Complete response was defined as the disappearance of all target lesions; partial response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions from baseline; stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease (PD).

    Time frame: Up to approximately 5 years

  4. Duration of Response

    Duration of Response is defined as the time from the first occurrence of a documented objective response to the time of relapse, as determined by blinded independent central review per RECIST v1.1, or death from any cause, whichever comes first.

    Time frame: Up to approximately 5 years

  5. Percentage of Participants Alive and Progression-Free at 12 Months (APF12)

    Progression-free survival was defined as the time from the date of randomization to the date of the first objectively tumor progression as assessed by the blinded independent central review per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by radiological assessment) or death (any cause) on or prior to the clinical cut-off date, which ever occurred first

    Time frame: Up to 12 months

  6. Percentage of Participants Alive and Progression-free at 18 Months (APF18)

    Progression-free survival was defined as the time from the date of randomization to the date of the first objectively tumor progression as assessed by the blinded independent central review per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by radiological assessment) or death (any cause) on or prior to the clinical cut-off date, which ever occurred first

    Time frame: Up to approximately 18 months

  7. Time to Distant Metastasis (TTDM)

    TTDM was defined as the time from the date of randomization until the first date of distant metastasis or death in the absence of distant metastasis. Distant metastasis was defined as any new lesion that is outside of the radiation field according to RECIST v1.1 or proven by biopsy.

    Time frame: Up to approximately 5 years

  8. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    TEAEs include any adverse events (AEs) that had an onset date or a worsening in severity from baseline on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of new anticancer therapy, whichever occurred first. TEAEs also included all immune-related AEs recorded up to 90 days after the last dose of tislelizumab or placebo, regardless of whether or not the particpant started a new anticancer therapy. In addition, any serious AE with an onset date more than 30 days after the last dose of study drug that is assessed by the investigator as related to study drug were considered a TEAE."

    Time frame: From first dose of study drug up to study withdrawal date of 26 June 2019; 15 days.

  9. Number of Participants With Lung Cancer Symptoms Assessed by the Corresponding Domains of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC-QLQ-C30) and Lung-Cancer Specific QLQ-LC13

    The EORTC QLQ-C30 is a 30-item, questionnaire assessing quality of life (QoL), psychosocial burden and physical symptoms. It is classified into 15 domains: 5 functional subscales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning); 3 multi-item symptom subscales (fatigue, nausea/vomiting, and pain); each item is measured on a 4 point response scale; (not at all, a little, quite a bit, very much), with the exception of the 2 items measuring global health and QoL, (measured on a 7-point response scale). Scores are linearly transformed to 0 to 100 scores. Scores vary from 0 (worst) to 100 (best) for the functional dimensions and GHS, and from 0 (best) to 100 (worst) for the symptom dimensions; higher scores = better QoL, better functioning, or more severe symptoms, respectively. The LC13 covers 13 typical symptoms of lung cancer patients, such as coughing, pain, dyspnea, sore mouth, peripheral neuropathy, and hair loss.

    Time frame: Up to approximately 5 years

  10. Percentage of Participants Who Would Have Continued on to Monotherapy Phase

    Included the percentage of participants who would have received at least one dose of tislelizumab or placebo in the monotherapy phase before progression.

    Time frame: Up to approximately 5 years

07

Results

Posted Jul 15, 2020

Participant flow

One participant was enrolled in the United States before the study was terminated.

Participant flow — Overall Study
MilestoneTislelizumab + Concurrent Chemoradiotherapy -TislelizumabPlacebo + Concurrent Chemoradiotherapy -TislelizumabPlacebo + Concurrent Chemoradiotherapy - Placebo
Started010
Completed000
Not completed010
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryProgression-Free Survival (PFS)

Progression-free survival was defined as the time from the date of randomization to the date of the first objectively tumor progression as assessed by the blinded independent central review per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by radiological assessment) or death (any cause) on or prior to the clinical cut-off date, which ever occurred first. Stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for Progressive disease (PD)• Progressive Disease- At least a 20% increase in the sum of diameters of target lesions from nadir.

Time frame:
Up to approximately 5 years; date of randomization to the date of tumor progression or death; until study withdrawal date of 26 June 2019

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

Overall survival was defined as the time between randomization of treatment and death from any cause.

Time frame:
Up to approximately 5 years; date of randomization to date of death from any cause.

No measurements were reported for this outcome.

SecondaryOverall Survival at 24 Months

Overall survival was defined as the time between randomization of treatment and death from any cause.

Time frame:
Up to approximately 24 months

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response

Overall Response was defined as percentage of participants who had a radiologic confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) guidelines, between Day 1 of treatment and subsequent anti-cancer therapy, death or study discontinuation. Complete response was defined as the disappearance of all target lesions; partial response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions from baseline; stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease (PD).

Time frame:
Up to approximately 5 years

No measurements were reported for this outcome.

SecondaryDuration of Response

Duration of Response is defined as the time from the first occurrence of a documented objective response to the time of relapse, as determined by blinded independent central review per RECIST v1.1, or death from any cause, whichever comes first.

Time frame:
Up to approximately 5 years

No measurements were reported for this outcome.

SecondaryPercentage of Participants Alive and Progression-Free at 12 Months (APF12)

Progression-free survival was defined as the time from the date of randomization to the date of the first objectively tumor progression as assessed by the blinded independent central review per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by radiological assessment) or death (any cause) on or prior to the clinical cut-off date, which ever occurred first

Time frame:
Up to 12 months

No measurements were reported for this outcome.

SecondaryPercentage of Participants Alive and Progression-free at 18 Months (APF18)

Progression-free survival was defined as the time from the date of randomization to the date of the first objectively tumor progression as assessed by the blinded independent central review per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by radiological assessment) or death (any cause) on or prior to the clinical cut-off date, which ever occurred first

Time frame:
Up to approximately 18 months

No measurements were reported for this outcome.

SecondaryTime to Distant Metastasis (TTDM)

TTDM was defined as the time from the date of randomization until the first date of distant metastasis or death in the absence of distant metastasis. Distant metastasis was defined as any new lesion that is outside of the radiation field according to RECIST v1.1 or proven by biopsy.

Time frame:
Up to approximately 5 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

TEAEs include any adverse events (AEs) that had an onset date or a worsening in severity from baseline on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of new anticancer therapy, whichever occurred first. TEAEs also included all immune-related AEs recorded up to 90 days after the last dose of tislelizumab or placebo, regardless of whether or not the particpant started a new anticancer therapy. In addition, any serious AE with an onset date more than 30 days after the last dose of study drug that is assessed by the investigator as related to study drug were considered a TEAE."

Time frame:
From first dose of study drug up to study withdrawal date of 26 June 2019; 15 days.
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsTislelizumab + Concurrent Chemoradiotherapy -TislelizumabPlacebo + Concurrent Chemoradiotherapy -TislelizumabPlacebo + Concurrent Chemoradiotherapy - Placebo
≥ 1 TEAE—1—
≥ 1 Treatment Related TEAE—1—
SecondaryNumber of Participants With Lung Cancer Symptoms Assessed by the Corresponding Domains of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC-QLQ-C30) and Lung-Cancer Specific QLQ-LC13

The EORTC QLQ-C30 is a 30-item, questionnaire assessing quality of life (QoL), psychosocial burden and physical symptoms. It is classified into 15 domains: 5 functional subscales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning); 3 multi-item symptom subscales (fatigue, nausea/vomiting, and pain); each item is measured on a 4 point response scale; (not at all, a little, quite a bit, very much), with the exception of the 2 items measuring global health and QoL, (measured on a 7-point response scale). Scores are linearly transformed to 0 to 100 scores. Scores vary from 0 (worst) to 100 (best) for the functional dimensions and GHS, and from 0 (best) to 100 (worst) for the symptom dimensions; higher scores = better QoL, better functioning, or more severe symptoms, respectively. The LC13 covers 13 typical symptoms of lung cancer patients, such as coughing, pain, dyspnea, sore mouth, peripheral neuropathy, and hair loss.

Time frame:
Up to approximately 5 years

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Would Have Continued on to Monotherapy Phase

Included the percentage of participants who would have received at least one dose of tislelizumab or placebo in the monotherapy phase before progression.

Time frame:
Up to approximately 5 years

No measurements were reported for this outcome.

Adverse events

Collected over From first dose of study drug up to study withdrawal date of 26 June 2019; 15 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tislelizumab + Concurrent Chemoradiotherapy -Tislelizumab———
Placebo + Concurrent Chemoradiotherapy -Tislelizumab0/1 (0%)0/1 (0%)1/1 (100%)
Placebo + Concurrent Chemoradiotherapy - Placebo———
Most frequent other events
Most frequent other events
EventTislelizumab + Concurrent Chemoradiotherapy -TislelizumabPlacebo + Concurrent Chemoradiotherapy -TislelizumabPlacebo + Concurrent Chemoradiotherapy - Placebo
CoughRespiratory, thoracic and mediastinal disorders—1/1—
Infusion Related ReactionInjury, poisoning and procedural complications—1/1—
MUSCLE CRAMPINGMusculoskeletal and connective tissue disorders—1/1—
NECK PAINMusculoskeletal and connective tissue disorders—1/1—

Baseline characteristics

Intent to Treat Population included all randomized participants regardless of whether the participant received any study drug or had any efficacy assessments performed.

Age, Categorical
Age, Categorical(Participants)Tislelizumab + Concurrent Chemoradiotherapy -TislelizumabPlacebo + Concurrent Chemoradiotherapy -TislelizumabPlacebo + Concurrent Chemoradiotherapy - PlaceboTotal
<=18 years—0—0
Between 18 and 65 years—1—1
>=65 years—0—0
Sex: Female, Male
Sex: Female, Male(Participants)Tislelizumab + Concurrent Chemoradiotherapy -TislelizumabPlacebo + Concurrent Chemoradiotherapy -TislelizumabPlacebo + Concurrent Chemoradiotherapy - PlaceboTotal
Female0101
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tislelizumab + Concurrent Chemoradiotherapy -TislelizumabPlacebo + Concurrent Chemoradiotherapy -TislelizumabPlacebo + Concurrent Chemoradiotherapy - PlaceboTotal
Hispanic or Latino0000
Not Hispanic or Latino0101
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tislelizumab + Concurrent Chemoradiotherapy -TislelizumabPlacebo + Concurrent Chemoradiotherapy -TislelizumabPlacebo + Concurrent Chemoradiotherapy - PlaceboTotal
Caucasian0101
08

Study locations

164 sites
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Cancer Specialists of North Florida - Jacksonville
    Jacksonville, Florida 32258-5472, United States
  • Bond Clinic, P.A.
    Winter Haven, Florida 33881, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Fort Wayne Medical Oncology and Hematology
    Fort Wayne, Indiana 46845, United States
  • Appalachian Regional Healthcare, Inc.
    Hazard, Kentucky 41701, United States
  • Norton Healthcare - Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Center For Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Dayton Physicians, LLC
    Kettering, Ohio 45409, United States
  • Mercy Health Youngstown Hospital, LLC
    Youngstown, Ohio 44504, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Millennium Oncology
    Houston, Texas 77090, United States
  • Medical Oncology Associates, P.S.
    Spokane, Washington 99208, United States
  • Universitair Ziekenhuis Brussel
    Brussels, 1090, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, 100021, China
  • Chinese PLA General Hospital / 307 Hospital
    Beijing, 100071, China
  • Beijing Cancer Hospital - Beijing Institute for Cancer Research
    Beijing, 100142, China
  • Bengbu Medical College - First Affiliated Hospital
    Bengbu Shi, 233004, China
  • Jilin Province Cancer Hospital
    Changchun Shi, 130012, China
  • First Hospital of Jilin University
    Changchun, 130021, China
  • Central South University - Xiangya School of Medicine - Hunan Cancer Hospital
    Changsha-shi, 410013, China
  • Central South University - Xiangya School of Medicine - Hunan Cancer Hospital
    Changsha, 410013, China
  • Sichuan Cancer Hospital & Institute
    Chengdu, 610041, China
  • Sichuan University - West China Hospital
    Chengdu, 610041, China
  • Foshan First People's Hospital
    Foshan, 528000, China
  • Fujian Medical University - Fujian Provincial Cancer Hospital
    Fuzhou Shi, 350014, China
  • Cancer Center of Guangzhou Medical University
    Guangzhou, 510095, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, 510120, China
  • Zhejiang University School of Medicine - The Second Affiliated Hospital
    Hangzhou, 310016, China
  • Zhejiang Medical University - Zhejiang Cancer Hospital
    Hangzhou, 310022, China
  • The First Affiliated Hospital of Harbin Medical University
    Harbin, 150081, China
  • Yunnan Cancer Hospital
    Kunming Shi, 650118, China
  • Guangxi Tumour Institute and Hospital
    Nanning, 530021, China
  • Nantong Tumor Hospital
    Nantong, 226361, China
  • Shanghai Chest Hospital
    Shanghai Shi, 200030, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
  • Chongqing Cancer Hospital
    Shapingbaqu, 400030, China
  • Liaoning Cancer Hospital & Institute
    Shenyang Shi, 110042, China
  • The First Hospital of Xinjiang Medical University
    Urumqi, 830054, China
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, 430022, China
  • Zhongnan Hospital of Wuhan University
    Wuhan, 430023, China
  • Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, 430030, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an City, 710061, China
  • First Hospital of Xiamen
    Xiamen, 361003, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, 221002, China
  • Zhengzhou University (ZZU) - Henan Cancer Hospital
    Zhengzhou, 450008, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, 450052, China
  • Tampereen yliopistollinen sairaala
    Tampere, 33521, Finland
  • Turku University Hospital
    Turku, 20521, Finland
  • Centre Francois Baclesse
    Caen Cedex 5, 14076, France
  • Clinique Victor Hugo
    Le Mans, 72015, France
  • Institut de Cancerologie de l'Ouest (ICO) - Saint-Herblain
    Saint Herblain, 44805, France
  • Medical Study Company NORD-WEST GmbH Oncology Aurich
    Aurich, 26603, Germany
  • Helios Klinikum Emil Von Behring
    Berlin, 14165, Germany
  • Florence Nightingale KH der Kaiserwerther Diakonie
    Dusseldorf, 40489, Germany
  • Klinikum Esslingen GmbH
    Esslingen Am Neckar, 73730, Germany
  • Asklepios Fachkliniken Muenchen Gauting
    Gauting, 82131, Germany
  • Oncological practice Goslar
    Goslar, 38642, Germany
  • Evangelisches Krankenhaus Hamm
    Hamm, 59063, Germany
  • Health Nordhessen Holding AG - Klinikum Kassel - Medical Clinic IV
    Kassel, 34125, Germany
  • Kliniken der Stadt Koln gGmbH - Krankenhaus Merheim
    Koln, 51109, Germany
  • Klinik Loewenstein gGmbH
    Loewenstein, 74245, Germany
  • LMU Klinikum der Universität
    München, 81377, Germany
  • St. Antonius-Hospital
    Schweiler, 52249, Germany
  • Medizinische Studiengesellschaft Nord-West
    Westerstede, 26655, Germany
  • Sotiria Chest Hospital of Athens
    Athens, 11527, Greece
  • IASO General
    Athens, 15562, Greece
  • University General Hospital of Heraklion
    Heraklion, 71110, Greece
  • Agioi Anargyroi Cancer Hospital
    Kifissia, 14564, Greece
  • Metaxa Cancer Hospital of Piraeus
    Piraeus, 18537, Greece
  • Interbalkan Medical Center of Thessaloniki
    Pylaia, 570 01, Greece
  • University General Hospital of Patras
    Rio Patras, 26500, Greece
  • Bioclinic Thessaloniki Galinos clinic
    Thessaloniki, 54622, Greece
  • EUROMEDICA General Clinic of Thessaloniki
    Thessaloniki, 54645, Greece
  • Papageorgiou General Hospital of Thessaloniki
    Thessaloniki, 56429, Greece
  • Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
    Szekesfehervar, 8000, Hungary
  • Pulmonary Institute Torokbalint
    Torokbalint, 2045, Hungary
  • Beacon Hospital
    Dublin, D18 AK68, Ireland
  • St James Hospital
    Dublin, Dublin 8, Ireland
  • MidWestern Regional Hospital
    Limerick, Ireland
  • Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele - Ospedale Gaspare Rodolico
    Catania, 95123, Italy
  • IRCCS AziendaOspedaliera Universitaria San Martino
    Genova, 16132, Italy
  • Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.)
    Meldola, 47014, Italy
  • Universita Campus Bio-Medico di Roma
    Roma, 00128, Italy
  • Istituto Nazionale Tumori Regina Elena di Roma
    Roma, 00144, Italy
  • Osaka Prefectural Medical Center for Respiratory and Allergic Diseases
    Habikino-shi, 583-8588, Japan
  • Kansai Medical University Hospital
    Hirakata-shi, 573-1191, Japan
  • Hiroshima University Hospital
    Hiroshima, 734-8551, Japan
  • Kanazawa University Hospital
    Kanazawa-shi, Japan
  • Matsusaka Municipal Hospital
    Matsusaka-shi, 515-8544, Japan
  • Toranomon Hospital
    Minato-ku, 105-8470, Japan
  • Iwate Medical University Hospital
    Morioka, 020-8505, Japan
  • National Hospital Organization - Nagoya Medical Center
    Nagoya-shi, 460-0001, Japan
  • Nagoya University Hospital
    Nagoya-shi, 466-8560, Japan
  • Niigata Cancer Center Hospital
    Niigata-shi, 951-8566, Japan
  • Osaka City University Hospital
    Osaka, 545-8586, Japan
  • Gunma Prefectural Cancer Center
    Ota-ku, 373-8550, Japan

Showing the first 100 of 164 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Jun 2019, 1 month.

Results were first posted in Jul 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2018
First posted
Nov 19, 2018
StartActual
May 22, 2019
Primary completionActual
Jun 26, 2019
CompletionActual
Jun 26, 2019
Results first posted
Jul 15, 2020
Last update
Jul 15, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03745222
Lead sponsor
Celgene
Collaborators
BeiGene
Responsible party
Sponsor
First posted
Nov 19, 2018
Start date
May 22, 2019
Primary completion
Jun 26, 2019
Completion
Jun 26, 2019
Results posted
Jul 15, 2020
Last update
Jul 15, 2020

Study contacts

Marie Nguyen, MD
study director · Celgene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion